Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 4/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | ALPI | P09923 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | XIAP | P98170 | 1/20 | 1.00 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.69 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.69 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.69 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | LTA4H | P09960 | 1/20 | 0.59 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | FYN | P06241 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Phenylalanine SCHEMBL1331077 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL1449128 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL1332173 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL1331829 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL8835931 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL23159186 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL1331777 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL2785094 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL1330932 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL1331205 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1261623-B1 | NEW RETINOL DERIVATIVES, THE METHOD OF PREPARATIONS AND THE USES THEREOF | CHEBIGEN INC (KR) | 2009-11-04 | — | — | EP | claimed |
| EP-0652229-A2 | Oligopeptides with fungicidal activity | ISAGRO S.p.A. (IT) | 1995-05-10 | — | — | EP | claimed |
| WO-2022213201-A1 | APPARATUS AND METHODOLOGIES FOR DETECTION, DIAGNOSIS, AND PROGNOSIS OF BRAIN INJURY | UTI LIMITED PARTNERSHIP (CA) | 2022-10-13 | — | — | WO | disclosed |
| WO-2016183093-A1 | INHIBITORS OF VIRUSES | UNIVERSITY OF KANSAS (US) | 2016-11-17 | — | — | WO | disclosed |
| EP-2449488-A1 | METHOD FOR NORMALIZATION IN METABOLOMICS ANALYSIS METHODS WITH ENDOGENOUS REFERENCE METABOLITES | BIOCRATES Life Sciences AG (AT) | 2012-05-09 | — | — | EP | disclosed |
| EP-2427773-A1 | METHOD OF DIAGNOSING ASPHYXIA | Keller, Matthias (DE) | 2012-03-14 | — | — | EP | disclosed |
| CN-101497655-B | Polypeptide hydration salt compound and use for anti-depression aspect | BEIJING YUANSEN KANGTAI MEDICINE CO LTD | 2011-11-23 | — | — | CN | disclosed |
| US-20110275708-A1 | POLYCYCLIC COMPOUNDS AND METHODS RELATED THERETO | CORNELL UNIVERSITY (US) | 2011-11-10 | — | — | US | disclosed |
| CN-1973037-B | Process for producing dipeptide or dipeptide derivative | KYOWA HAKKO KOGYO KK | 2011-10-19 | — | — | CN | disclosed |
| US-7989434-B2 | Heterocyclic self-immolative linkers and conjugates | SEATTLE GENETICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| WO-2011000753-A1 | METHOD FOR NORMALIZATION IN METABOLOMICS ANALYSIS METHODS WITH ENDOGENOUS REFERENCE METABOLITES | BIOCRATES LIFE SCIENCES AG (AT) | 2011-01-06 | — | — | WO | disclosed |
| CN-1286535-C | Adsorbent for eliminating hepatitis C virus, adsorber, and adsorption method | KANEKA CORP (JP) | 2006-11-29 | — | — | CN | disclosed |
| US-20050256030-A1 | for linking drug moieties to ligands; comprises a peptide sequence that is a substrate for an intracellular enzyme, for example a cathepsin, that cleaves the peptide at an amide bond | SEAGEN INC. | 2005-11-17 | — | — | US | disclosed |
| CN-1420793-A | Absorbents for dilated cardiomyopathy | KANEKA CORP (JP) | 2003-05-28 | — | — | CN | disclosed |
| CN-1407993-A | Gene recombinant antibody and its fragment | KYOWA HAKKO KOGYO KK (JP) | 2003-04-02 | — | — | CN | disclosed |
| EP-0624377-B1 | Lysosomal enzyme-cleavable antitumor drug conjugates | BRISTOL MYERS SQUIBB CO (US) | 2002-01-23 | — | — | EP | disclosed |
| US-6214345-B1 | ANTITUMOR AGENTS; DRUG CONJUGATES WHICH ARE SELECTIVELY ACTIVATIBLE AT THE SITE OF THE TUMOR | BRISTOL-MYERS SQUIBB CO. | 2001-04-10 | — | — | US | disclosed |
| CN-1251048-A | Adsorbent, adsorber and adsorption method for eliminating hepatitis C virus | KANEKA CORP (JP) | 2000-04-19 | — | — | CN | disclosed |
| CN-1100426-A | Lysosomal enzyme-cleavable antitumor drug conjugates | BRISTOL MYERS SQUIBB CO (US) | 1995-03-22 | — | — | CN | disclosed |
| EP-0624377-A2 | Lysosomal enzyme-cleavable antitumor drug conjugates | Bristol-Myers Squibb Company (US) | 1994-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256030-A1 | for linking drug moieties to ligands; comprises a peptide sequence that is a substrate for an intracellular enzyme, for example a cathepsin, that cleaves the peptide at an amide bond | CTSS, CTSE, CTSL | SLC7A5 510/4885PTGS1 4140/4885ALPI 2563/4885 |
| US-20110275708-A1 | POLYCYCLIC COMPOUNDS AND METHODS RELATED THERETO | PKD1, THPO, CCNO | SLC7A5 2579/4885PTGS1 34/4885ALPI 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.